In this single-center study, we confirmed the beneficial effectiveness of omalizumab in Chinese patients with difficult-to-treat CRSwNP and asthma by employing a variety of minimally invasive or noninvasive evaluation methods, such as the VAS, SNOT-22, ACT, LMS, LKS, NPS, NSE, PFT, and routine blood tests. The gene discussed is ENO2; the disease is chronic rhinosinusitis with nasal polyps.